News Sentiment

VKTX sentiment intelligence

Viking Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 37.08 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-4.6% over one week, +22.1% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -4.6% Price reacting lower
Trend fit Trend active 22.1% over four weeks
Fair value -0.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 27
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
Simply Wall Street 6
TradingView 6
Stocktwits 4
Quartr 4
simplywall.st 3
Stock Titan 2
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 14
Guidance 3
Analyst action 2
Deals and strategy 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-55 of 55
Finviz Direct company coverage

VKTX - Viking Therapeutics Inc Options

This article provides a detailed financial overview of Viking Therapeutics Inc (VKTX), including its last closing price, market capitalization, key financial ratios, and performance metrics. It also lists insider ownership and transactions, institutional ownership, and short inte

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 01:40
Source
Finviz
The Globe and Mail Direct company coverage

Is Viking Therapeutics Stock Going to $100?

Viking Therapeutics is a clinical-stage biotech company with promising weight-loss drug candidates, particularly VK2735, which mimics GLP-1 and GIP hormones. The company is undergoing Phase 3 trials for VK2735 and developing an oral formulation, with potential for its stock to re

Tone
Positive 65/100
Event
Market update
Published
01 Jul 2026 18:40
Source
The Globe and Mail
Simply Wall Street Direct company coverage

Why Viking Therapeutics (VKTX) Is Up 22.2% After Advancing VK3019 Into First-in-Human Obesity Trial

Viking Therapeutics' stock rose 22.2% after it advanced VK3019, a new obesity treatment, into a Phase 1 clinical trial following FDA clearance. This move expands Viking's metabolic disease pipeline, complementing its late-stage VK2735 program and aiming to build a diverse obesity

Tone
Positive 81/100
Event
Market update
Published
30 Jun 2026 17:09
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Viking Therapeutics (VKTX) Starts A Phase 1 Obesity Trial, Is The Upside Already Priced In?

Viking Therapeutics (VKTX) has commenced a Phase 1 trial for VK3019, its new dual amylin and calcitonin receptor agonist targeting obesity, sparking investor interest as the stock has already seen significant gains. Despite a strong market run with shares up over 5x in five years

Tone
Positive 62/100
Event
Market update
Published
29 Jun 2026 13:41
Source
Simply Wall Street
TradingView Direct company coverage

ETFs Investing in Viking Therapeutics, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Viking Therapeutics, Inc. The ETFs are sorted by their market value dedicated to Viking Therapeutics, Inc. and include details like the ETF's issuer, management style, focus, expense ratio, assets under m

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 02:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Viking Therapeutics, Inc. – NASDAQ:VKTX

This article focuses on the enterprise value to EBITDA forward for Viking Therapeutics, Inc. (NASDAQ: VKTX) as observed on TradingView. It appears to be a stub or a section of a larger financial data presentation, providing a specific financial metric for the company. The content

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 17:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Viking Therapeutics, Inc. – NASDAQ:VKTX

The article focuses on the enterprise value to EBIT forward for Viking Therapeutics, Inc. (NASDAQ: VKTX) and provides financial data for the company. It serves as a financial information page on TradingView, listing various related metrics and offering general market data without

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 15:39
Source
TradingView
Streetwise Reports Direct company coverage

Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1

Viking Therapeutics has initiated a Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist, broadening its obesity treatment pipeline. This new candidate could complement existing GLP-1 therapies like VK2735, which is currently in Phase 3 trials for both subcutan

Tone
Positive 74/100
Event
Market update
Published
27 Jun 2026 09:39
Source
Streetwise Reports